Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ZK2501
- Development stage
- Preclinical
- Lead developer
- Lee's Pharmaceutical
- Administration
- Oral
01
Overview
ZK2501 is a preclinical-stage therapeutic candidate being developed by Lee's Pharmaceutical for the treatment of solid tumors. As of 2024, the asset is in the early stages of development, and specific details regarding its molecular target and modality have not been publicly disclosed by the sponsor. It is part of Lee's Pharmaceutical's internal oncology pipeline, which includes several early-stage assets aimed at addressing unmet needs in cancer therapy.
Beyond the preview
Go deeper on ZK2501.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ZK2501.